Advertisement

Pharmaceutical & Diagnostic Innovation

, Volume 3, Issue 11, pp 13–16 | Cite as

NO Time for Old Drugs

Novel Nitric Oxide Therapies from NicOx
Emerging Technology
  • 5 Downloads

Executive summary

The ubiquitous physiological effects of the nitric oxide (NO) messenger molecule mean that NO-based therapeutics are potentially useful in most areas of medicine. The French company NicOx is pursuing a unique approach to this technology by combining NO-releasing compounds with established pharmaceuticals. The dual mechanism of such agents is hoped to offer significant therapeutic advantages. NicOx is mainly focused on applying this technology platform to cardiovascular disease, inflammatory disorders and pain, but also has programs in development for neurodegenerative, respiratory, liver and dermatological diseases.

Underlining the potential of the NicOx approach are collaborations with the pharmaceutical giants Pfizer and Merck & Co., as well as smaller pharma and biotech companies. NicOx currently has seven compounds in clinical trials, with its lead candidates being a naproxen derivative scheduled to enter phase III trials soon for osteoarthritis (HCT-3012), and an...

Keywords

Nitric Oxide Nitric Oxide Synthases Naproxen Allergic Rhinitis Rofecoxib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327 (6122): 524–6PubMedCrossRefGoogle Scholar
  2. 2.
    Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333 (6174): 664–6PubMedCrossRefGoogle Scholar
  3. 3.
    European Biotechnology. NicOx. Change of price. Disappointing phase II data. New York: Lehman Brothers Global Equity Re-search, 2005Google Scholar
  4. 4.
    NicOx. NicOx announces results of a phase 2 trial for NCX 4016 in PAOD. Media release: 14 Nov 2005Google Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations